Invivyd, Inc. — Director's Dealing 2021

Aug 13, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adagio Therapeutics, Inc. (ADGI)
CIK: 0001832038
Period of Report: 2021-08-10

Reporting Person: Gerngross Tillman U. (Director, Chief Executive Officer, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-10	Common Stock	C	25860700	—	Acquired	27845995	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-10	Series A Preferred Stock	$	C	5000000	Disposed		Common Stock (25000000)	Indirect
2021-08-10	Series B Preferred Stock	$	C	44076	Disposed		Common Stock (220380)	Indirect
2021-08-10	Series C Preferred Stock	$	C	128064	Disposed		Common Stock (640320)	Indirect

Footnotes

F1: Each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted, without payment of additional consideration, into Common Stock on a 5:1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock and had no expiration date.

F2: These shares are held by Adimab, LLC (the "LLC"). The Reporting Person is an officer and member of the Board of Directors of the LLC and, as such, may be deemed to have shared voting and investment power with respect to the shares held by the LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.